Rodolfo F. Perini

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Belzutifan plus lenvatinib versus cabozantinib in post–PD-(L)1 renal cell carcinoma (RCC): Health-related quality-of-life (HRQoL) outcomes in the phase 3 LITESPARK-011 study.

  Journal of Clinical Oncology · 2026-05-28

• Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease–associated neoplasms.

  Journal of Clinical Oncology · 2026-05-27

• ctDNA analysis in participants with renal cell carcinoma treated with adjuvant pembrolizumab or placebo in the KEYNOTE-564 trial.

  Journal of Clinical Oncology · 2026-05-27 · 1 citations

• Belzutifan efficacy in von Hippel-Lindau disease-associated renal cell carcinoma versus natural history control arm

  JNCI Journal of the National Cancer Institute · 2026-03-23

• Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2026-03-01 · 1 citations

• Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.

  Journal of Clinical Oncology · 2026-03-01 · 3 citations

• Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.

  Journal of Clinical Oncology · 2026-03-01 · 1 citations

• KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2026-03-01 · 1 citations

• Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.

  Journal of Clinical Oncology · 2026-03-01

• Real-world treatment patterns and clinical outcomes among patients with metastatic renal cell carcinoma post immune-oncology and vascular endothelial growth factor receptor targeted therapies: A multicenter community oncology-based study

  Urologic Oncology Seminars and Original Investigations · 2026-02-26

• Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: Results of the glioblastoma expansion cohort

  Neuro-Oncology Advances · 2025-11-19 · 2 citations

• Postimmunotherapy and Vascular Endothelial Growth Factor Inhibitor Landscape in Advanced Renal Cell Carcinoma: Treatment Patterns, Costs, and Outcomes

  JCO Oncology Practice · 2025-10-13 · 1 citations

• 13Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005)

  The Oncologist · 2025-10-01

• 42The impact of belzutifan on tumor reduction procedures and healthcare resource utilization in von hippel–lindau (VHL) disease

  The Oncologist · 2025-10-01

• Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

  Nature Medicine · 2025-08-01 · 35 citations

• Hypoxia-inducible factor-2α (HIF-2α) inhibitor belzutifan in von Hippel-Lindau (VHL) disease–associated neoplasms: 5-year follow-up of the phase 2 LITESPARK-004 study.

  Journal of Clinical Oncology · 2025-05-28 · 4 citations

• Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2025-05-28 · 4 citations

• Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies

  Cancers · 2025-04-25 · 1 citations

• Longitudinal Evaluation of Clear-cell Renal Cell Carcinoma in von Hippel-Lindau Disease

  European Urology · 2025-04-23 · 8 citations

• Abstract 2163: Inhibition of HIF2A increases efficacy of immune checkpoint blockade in renal cell carcinoma

  Cancer Research · 2025-04-21